Healio
FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia
Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
WebMD
Cardamyst: FDA Approves First Rapid-Acting Self-Use Nasal Spray for Sudden Fast Heartbeats (PSVT)
What Is Cardamyst, and Why Does It Matter? Cardamyst (etripamil) is a new nasal spray for treating sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT), and ...
FiercePharma
Milestone wins 1st-ever FDA approval with green light for heart arrhythmia nasal spray
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given Milestone Pharmaceuticals its first FDA approval in its 22-year history. The ...
Nasdaq
MIST Hits A Milestone: FDA Approves First-Ever Self-Administered Nasal Spray For PSVT
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...
TCTMD
Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT
The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...
Benzinga.com
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
The approval marks Cardamyst as the first FDA-approved treatment in over 30 years for more than 2 million Americans with PSVT. Cardamyst nasal spray is a novel and rapid-acting calcium channel blocker ...